Armata Pharmaceuticals, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, a bacteriophage therapeutic for complicated Staphylococcus aureus bacteremia (MRSA/MSSA). The designation is supported by Phase 1b/2a diSArm study data showing 100% clinical response maintenance at 28 days with AP-SA02 plus antibiotics versus 75% with placebo plus antibiotics, with no serious adverse events. AP-SA02 now holds Breakthrough Therapy, Fast Track, and QIDP designations; Phase 3 anticipated to initiate H2 2026, supported by $28.7M Department of War award through MTEC.
Why this rating
Breakthrough Therapy designation for lead pipeline asset of $21.1M-market company materially accelerates regulatory pathway and validates clinical promise; directly supports path to Phase 3 initiation and potential first-to-market advantage in serious infection indication.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $6.27 ▲ 1.00% | at our read · unknown $6.21 | +10 min · unknown $6.04 ▼ 2.74% | +30 min · unknown $6.18 ▼ 0.52% | +1 hr · unknown $6.29 ▲ 1.21% | +4 hrs · unknown $5.50 ▼ 11.43% |
The stock had already moved -0.99% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.